ASND vs. FINV

Last updated Apr 1, 2026

Compare and contrast key facts about Ascendis Pharma A/S (ASND) and FinVolution Group (FINV).

Performance

ASND vs. FINV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ascendis Pharma A/S (ASND) and FinVolution Group (FINV). The values are adjusted to include any dividend payments, if applicable.

ASND vs. FINV - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ASND Ascendis Pharma A/S	7.26%	54.89%	9.31%	3.13%	-9.22%	-19.34%	19.88%	122.06%	56.39%	10.88%
FINV FinVolution Group	-8.41%	-20.07%	45.47%	4.39%	6.39%	89.23%	8.51%	-22.85%	-49.37%	-45.64%

Fundamentals

Market Cap ASND : $14.04B FINV : $1.27B
EPS ASND : -$3.67 FINV : $9.51
PS Ratio ASND : 19.79 FINV : 0.09
Total Revenue (TTM) ASND : $717.81M FINV : $13.53B
Gross Profit (TTM) ASND : $619.30M FINV : $10.64B
EBITDA (TTM) ASND : -$80.69M FINV : $3.00B

Returns By Period

In the year-to-date period, ASND achieves a 7.26% return, which is significantly higher than FINV's -8.41% return.

ASND

• 1D: 4.75%
• 1M: -2.04%
• YTD: 7.26%
• 6M: 15.05%
• 1Y: 46.75%
• 3Y*: 28.73%
• 5Y*: 11.89%
• 10Y*: 28.43%

FINV

• 1D: 1.70%
• 1M: -14.77%
• YTD: -8.41%
• 6M: -35.01%
• 1Y: -48.38%
• 3Y*: 9.76%
• 5Y*: -2.92%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ASND vs. FINV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ASND

ASND Risk / Return Rank: 82
ASND Sharpe Ratio Rank: 81
ASND Sortino Ratio Rank: 77
ASND Omega Ratio Rank: 72
ASND Calmar Ratio Rank: 90
ASND Martin Ratio Rank: 88

FINV

FINV Risk / Return Rank: 8
FINV Sharpe Ratio Rank: 4
FINV Sortino Ratio Rank: 6
FINV Omega Ratio Rank: 7
FINV Calmar Ratio Rank: 10
FINV Martin Ratio Rank: 14

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ASND vs. FINV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ascendis Pharma A/S (ASND) and FinVolution Group (FINV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ASND	FINV	Difference
Sharpe ratio Return per unit of total volatility	1.29	-1.01	+2.30
Sortino ratio Return per unit of downside risk	1.95	-1.49	+3.44
Omega ratio Gain probability vs. loss probability	1.23	0.82	+0.40
Calmar ratio Return relative to maximum drawdown	3.96	-0.87	+4.83
Martin ratio Return relative to average drawdown	9.47	-1.38	+10.85
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ASND vs. FINV - Sharpe Ratio Comparison

The current ASND Sharpe Ratio is 1.29, which is higher than the FINV Sharpe Ratio of -1.01. The chart below compares the historical Sharpe Ratios of ASND and FINV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ASND	FINV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.29	-1.01	+2.30
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.25	-0.06	+0.31
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.56	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.49	-0.11	+0.60

Correlation

The correlation between ASND and FINV is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ASND vs. FINV - Dividend Comparison

ASND has not paid dividends to shareholders, while FINV's dividend yield for the trailing twelve months is around 5.78%.

	TTM	2025	2024	2023	2022	2021	2020	2019
ASND Ascendis Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
FINV FinVolution Group	5.78%	5.30%	3.49%	4.39%	4.13%	3.45%	4.49%	7.17%

Drawdowns

ASND vs. FINV - Drawdown Comparison

The maximum ASND drawdown since its inception was -61.72%, smaller than the maximum FINV drawdown of -89.64%. Use the drawdown chart below to compare losses from any high point for ASND and FINV.

Drawdown Indicators

	ASND	FINV	Difference
Max Drawdown Largest peak-to-trough decline	-61.72%	-89.64%	+27.92%
Max Drawdown (1Y) Largest decline over 1 year	-12.09%	-56.42%	+44.33%
Max Drawdown (5Y) Largest decline over 5 years	-60.46%	-70.54%	+10.08%
Max Drawdown (10Y) Largest decline over 10 years	-61.72%	—	—
Current Drawdown Current decline from peak	-5.52%	-54.81%	+49.29%
Average Drawdown Average peak-to-trough decline	-18.90%	-53.77%	+34.87%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.06%	35.66%	-30.60%

Volatility

ASND vs. FINV - Volatility Comparison

The current volatility for Ascendis Pharma A/S (ASND) is 9.38%, while FinVolution Group (FINV) has a volatility of 20.26%. This indicates that ASND experiences smaller price fluctuations and is considered to be less risky than FINV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ASND	FINV	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.38%	20.26%	-10.88%
Volatility (6M) Calculated over the trailing 6-month period	26.45%	37.63%	-11.18%
Volatility (1Y) Calculated over the trailing 1-year period	36.54%	48.08%	-11.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	48.36%	50.51%	-2.15%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	51.28%	72.22%	-20.94%

Financials

ASND vs. FINV - Profitability Comparison

The chart below illustrates the profitability comparison between Ascendis Pharma A/S and FinVolution Group over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ASND - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Ascendis Pharma A/S reported a gross profit of 217.98M and revenue of 245.18M. Therefore, the gross margin over that period was 88.9%.

FINV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported a gross profit of 2.15B and revenue of 2.98B. Therefore, the gross margin over that period was 72.0%.

ASND - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Ascendis Pharma A/S reported an operating income of 9.80M and revenue of 245.18M, resulting in an operating margin of 4.0%.

FINV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported an operating income of 475.99M and revenue of 2.98B, resulting in an operating margin of 16.0%.

ASND - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Ascendis Pharma A/S reported a net income of -33.25M and revenue of 245.18M, resulting in a net margin of -13.6%.

FINV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported a net income of 418.85M and revenue of 2.98B, resulting in a net margin of 14.1%.